| Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer H Ahmadzadehfar, E Eppard, S Kürpig, R Fimmers, A Yordanova, ... Oncotarget 7 (11), 12477, 2016 | 298 | 2016 |
| Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis K Rahbar, M Schmidt, A Heinzel, E Eppard, A Bode, A Yordanova, ... Journal of Nuclear Medicine 57 (9), 1334-1338, 2016 | 250 | 2016 |
| Theranostics in nuclear medicine practice A Yordanova, E Eppard, S Kürpig, RA Bundschuh, S Schönberger, ... OncoTargets and therapy, 4821-4828, 2017 | 236 | 2017 |
| Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 H Ahmadzadehfar, S Wegen, A Yordanova, R Fimmers, S Kürpig, ... European journal of nuclear medicine and molecular imaging 44, 1448-1454, 2017 | 174 | 2017 |
| PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall … K Rahbar, M Boegemann, A Yordanova, M Eveslage, M Schäfers, ... European journal of nuclear medicine and molecular imaging 45, 12-19, 2018 | 152 | 2018 |
| The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer A Yordanova, A Becker, E Eppard, S Kürpig, C Fisang, G Feldmann, ... European Journal of Nuclear Medicine and Molecular Imaging 44, 1473-1479, 2017 | 126 | 2017 |
| Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617 J Ferdinandus, E Eppard, FC Gaertner, S Kürpig, R Fimmers, ... Journal of Nuclear Medicine 58 (2), 312-319, 2017 | 120 | 2017 |
| Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu] Lu-PSMA-617 radioligand therapy H Ahmadzadehfar, S Schlolaut, R Fimmers, A Yordanova, S Hirzebruch, ... Oncotarget 8 (61), 103108, 2017 | 84 | 2017 |
| Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer K Rahbar, M Bögeman, A Yordanova, M Eveslage, M Schäfers, M Essler, ... European journal of nuclear medicine and molecular imaging 45, 243-246, 2018 | 83 | 2018 |
| Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour A Yordanova, K Mayer, P Brossart, MA Gonzalez-Carmona, ... European journal of nuclear medicine and molecular imaging 44, 1207-1214, 2017 | 70 | 2017 |
| Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer A Yordanova, P Linden, S Hauser, M Meisenheimer, S Kürpig, ... European journal of nuclear medicine and molecular imaging 46, 1073-1080, 2019 | 67 | 2019 |
| Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride H Ahmadzadehfar, S Zimbelmann, A Yordanova, R Fimmers, S Kürpig, ... Oncotarget 8 (33), 55567, 2017 | 65 | 2017 |
| The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy A Yordanova, MM Wicharz, K Mayer, P Brossart, MA Gonzalez-Carmona, ... Clinical Cancer Research 24 (19), 4672-4679, 2018 | 63 | 2018 |
| 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept H Ahmadzadehfar, K Azgomi, S Hauser, X Wei, A Yordanova, ... Journal of nuclear medicine 58 (3), 438-444, 2017 | 63 | 2017 |
| Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors A Yordanova, H Ahrens, G Feldmann, P Brossart, FC Gaertner, C Fottner, ... Clinical nuclear medicine 44 (5), e329-e335, 2019 | 58 | 2019 |
| The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu‐PSMA therapy A Yordanova, P Linden, S Hauser, G Feldmann, P Brossart, R Fimmers, ... The Prostate 80 (1), 17-27, 2020 | 38 | 2020 |
| Sorafenib in patients with refractory or recurrent multiple myeloma A Yordanova, D Hose, K Neben, M Witzens‐Harig, I Gütgemann, ... Hematological oncology 31 (4), 197-200, 2013 | 32 | 2013 |
| The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study H Ahmadzadehfar, R Matern, RP Baum, R Seifert, K Kessel, M Bögemann, ... European Journal of Nuclear Medicine and Molecular Imaging 48, 4067-4076, 2021 | 28 | 2021 |
| Diagnostic accuracy of [99mTc] Tc-Sestamibi in the assessment of thyroid nodules A Yordanova, S Mahjoob, P Lingohr, J Kalff, A Türler, H Palmedo, ... Oncotarget 8 (55), 94681, 2017 | 23 | 2017 |
| An impressive approach in nuclear medicine: Theranostics N Vahidfar, E Eppard, S Farzanehfar, A Yordanova, M Fallahpoor, ... PET clinics 16 (3), 327-340, 2021 | 20 | 2021 |
Prof. Dr. med. Hojjat Ahmadzadehfar,...Klinikum Westfalen, Department of Nuclear Medicine, Dortmund在 klinikum-westfalen.de 的电子邮件经过验证
